Physician
Cameo Carter MD, a Professional Corporation
Cameo Carter MD, a Professional Corporation was paid $1.83M by Medicaid between Jan 2018 and Nov 2024, across 68 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoCAMEO CARTER MD, A PROFESSIONAL CORPORATION
REDLANDS, CA 92373
REDLANDS, CA 92373
33aNPI1447404611assigned 11/13/2008
33bProvider typePediatrics Physician
28Total paid$1.83M
24GClaims70,094
24DCodes billed68
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pediatrics Physician providers in California
Rank by total paid#80 of 1,490
Median peer was paid$15K
This provider vs. median122×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,741 | $400K | |
| 2019 | 11,543 | $399K | |
| 2020 | 12,786 | $296K | |
| 2021 | 10,464 | $220K | |
| 2022 | 8,707 | $216K | |
| 2023 | 7,579 | $148K | |
| 2024incomplete | 7,274 | $149K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 14,258 | 12,418 | $681K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 8,817 | 8,078 | $252K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 11% | 4,226 | 3,861 | $193K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.6% | 3,576 | 3,440 | $157K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 6.6% | 1,583 | 1,167 | $120K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.8% | 1,652 | 1,481 | $87K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 4.7% | 4,806 | 4,660 | $86K |
| 92551 | 3.7% | 6,708 | 6,647 | $68K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.5% | 1,521 | 1,434 | $64K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 846 | 839 | $20K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 48 | 47 | $18K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 206 | 188 | $13K |
56 more codes
| 96127 | <1% | 2,307 | $12K | |
| 99173 | <1% | 3,298 | $7K | |
| 83655 | <1% | 498 | $7K | |
| 90686 | <1% | 949 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 331 | $4K |
| 99000 | <1% | 1,004 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 48 | $3K |
| 99383 | <1% | 48 | $3K | |
| 99381 | <1% | 56 | $3K | |
| 87634 | <1% | 40 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 214 | $2K |
| 90651 | <1% | 326 | $2K | |
| 85018 | <1% | 566 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 28 | $1K |
| 90670 | <1% | 293 | $1K | |
| 0071A | <1% | 22 | $870.00 | |
| 0072A | <1% | 22 | $870.00 | |
| 90697 | <1% | 64 | $824.93 | |
| 81001 | <1% | 236 | $785.62 | |
| 99382 | <1% | 12 | $727.92 | |
| 90672 | <1% | 26 | $579.95 | |
| 0002A | <1% | 25 | $560.00 | |
| 90633 | <1% | 210 | $456.19 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14 | $432.32 |
| 90656 | <1% | 44 | $396.00 | |
| 90715 | <1% | 92 | $309.69 | |
| 90710 | <1% | 62 | $258.46 | |
| 90619 | <1% | 29 | $258.39 | |
| 90680 | <1% | 38 | $231.86 | |
| G9920 | Screening performed and negative | <1% | 3,953 | $213.60 |
| 90696 | <1% | 55 | $142.60 | |
| 99188 | <1% | 16 | $92.68 | |
| 90744 | <1% | 72 | $80.63 | |
| 90734 | <1% | 97 | $44.57 | |
| 90698 | <1% | 74 | $9.28 | |
| 90700 | <1% | 17 | $9.08 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 611 | $5.40 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 27 | $3.57 |
| G8511 | Screening for depression documented as positive, follow-up plan not documented, reason not given | 0% | 93 | $0.00 |
| 99401 | 0% | 234 | $0.00 | |
| 99072 | 0% | 2,272 | $0.00 | |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 27 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 456 | $0.00 |
| 99051 | 0% | 115 | $0.00 | |
| 99408 | 0% | 65 | $0.00 | |
| 90707 | 0% | 13 | $0.00 | |
| 96160 | 0% | 14 | $0.00 | |
| 99174 | 0% | 301 | $0.00 | |
| 96161 | 0% | 1,400 | $0.00 | |
| 36416 | 0% | 29 | $0.00 | |
| 1220F | 0% | 236 | $0.00 | |
| H0049 | Alcohol and/or drug screening | 0% | 542 | $0.00 |
| 3351F | 0% | 148 | $0.00 | |
| S8110 | Peak expiratory flow rate (physician services) | 0% | 50 | $0.00 |
| 99441 | 0% | 15 | $0.00 | |
| 90716 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARTER, CAMEO (CEO AND MEDICAL DIRECTOR)